This article explores how GLP-1 medications, such as semaglutide, may influence emotional states and motivation, potentially leading to a phenomenon described as 'Ozempic personality' or the 'meh effect.' While some users report diminished pleasure and emotional flatness, clinic…
As GLP-1 medications gain popularity for weight loss, many users face the dilemma of whether they can stop the injections without regaining weight. Experts highlight the risks ass…
A recent study published in Nature Medicine investigates various interventions that could potentially slow down aging by analyzing epigenetic biomarkers. Researchers found that a…
A recent study published in the Journal of Investigative Dermatology suggests that GLP-1 drugs, commonly used for weight loss and diabetes management, may increase the risk of hai…
Recent research indicates that GLP-1 weight-loss drugs, such as semaglutide, may not only aid in weight management but also extend lifespan in older female mice. The study found t…
This article explores the complex relationship between exercise and appetite, highlighting that while exercise can initially suppress hunger, it may lead to increased appetite lat…
The FDA has granted approval for Mounjaro (tirzepatide) to reduce cardiovascular risk in individuals with type 2 diabetes, marking a significant development in diabetes management…
As metabolic health gains prominence in wellness discussions, the roles of NAD+ and GLP-1 therapies are increasingly scrutinized. This article clarifies how GLP-1 medications like…
A study published in Nature suggests that GLP-1 obesity drugs, such as semaglutide, may extend lifespan and improve health in older female mice. The research indicates that treate…
Researchers have developed a new artificial sweetener named sweelin, which is 3,500 times sweeter than sucrose and does not raise insulin levels. A clinical trial showed that swee…
At Vitafoods Asia 2026, SynbioTech will present its Lactiplantibacillus plantarum TWK10® and its microbiome CDMO platform, emphasizing its role in the evolving GLP-1 companion-nut…
Eli Lilly has reported a significant revenue increase of 47% in the second quarter, reaching $22.97 billion, despite a decline in employer insurance coverage for GLP-1 weight-loss…
Sofia Carson has come under fire for her appearance at the LACMA Art+Film Gala, with fans expressing concern over Hollywood's extreme beauty standards. The backlash highlights a g…
Beauty companies are racing to address the newly coined term 'Ozempic face' as they develop treatments for facial volume loss linked to rapid weight loss, further complicating the…
Fitness coach Jacob Zemer outlines key strategies to help adults slow muscle loss as they age. He emphasizes the importance of strength training, adequate protein intake, and qual…
NVIDIA and Eli Lilly have both reported impressive quarterly earnings, showcasing their respective growth potential. NVIDIA's revenue surged by over 105% year-over-year, driven by…
Novo Nordisk's stock fell by 7% after the company revealed its long-term growth strategy at a capital markets day, raising investor concerns about its ability to maintain its posi…
In a stunning twist of regulatory fate, the FDA has issued new hair-raising guidelines for users of GLP-1 drugs like Ozempic and Mounjaro, warning of a 37-68% increased risk of ha…